title: The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
abstract: BACKGROUND
  Typically, bevacizumab is initially infused for 90 min, then for 60 min, and subsequently for 30 min. The objective of the present study was to evaluate the safety profile of a short infusion of bevacizumab in Japanese colorectal cancer patients.
  
  
  METHODS
  The records of 58 patients who received bevacizumab (5 mg/kg) from June 2010 to September 2010 were reviewed. Bevacizumab was administered for 30 min at the first time. If patients had no infusion reaction, the infusion time was shortened to 10 min.
  
  
  RESULTS
  None of the 58 patients who received bevacizumab experienced an infusion reaction (95% confidence interval 0-6.2). The only serious adverse event related to bevacizumab infusion was grade 3 proteinuria in 2 patients.
  
  
  CONCLUSIONS
  Short infusion of bevacizumab for 30 min the first time and 10 min is safe and feasible.
authors: National Cancer Center Hospital, Gastrointestinal Medical Oncology Division, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. kenkato@ncc.go.jp.
authors: Tetsuji
authors: T
authors: Terazawa
authors: Hitoshi
authors: H
authors: Nishitani
authors: Ken
authors: K
authors: Kato
authors: Hironobu
authors: H
authors: Hashimoto
authors: Kohei
authors: K
authors: Akiyoshi
authors: Satoru
authors: S
authors: Iwasa
authors: Takako Eguchi
authors: TE
authors: Nakajima
authors: Tetsuya
authors: T
authors: Hamaguchi
authors: Yasuhide
authors: Y
authors: Yamada
authors: Yasuhiro
authors: Y
authors: Shimada
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: Bevacizumab; feasibility; short infusion